Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE...

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Outcomes for patients with peripheral T-cell lymphoma (PTCL) who do not achieve complete response (CR) or relapse after initial treatment are poorly understood due to a lack of prospective data.
• PTCL is an aggressive hematologic malignancy with limited treatment options for refractory or relapsed cases.

Purpose of the Study:

• To analyze and compare treatment patterns and outcomes for patients with primary refractory versus relapsed PTCL within the COMPLETE prospective registry.
• To identify disparities in treatment and survival between refractory and relapsed PTCL populations.

Main Methods:

• The COMPLETE registry prospectively enrolled 499 patients with aggressive T-cell lymphomas at US academic and community sites.
• Evaluated 420 patients: 97 with primary refractory disease and 58 with relapsed disease, based on strict response and progression criteria.
• Compared second-line treatment regimens and outcomes, including objective response rate (ORR) and overall survival (OS).

Main Results:

• Relapsed PTCL patients received single-agent therapies more often in the second-line setting (52% vs. 28%) and achieved higher ORRs (61% vs. 40%) and CR rates (41% vs. 14%) compared to refractory patients.
• Relapsed patients had significantly longer median overall survival (29.1 months) than refractory patients (12.3 months).
• Refractory PTCL patients were less likely to receive newer active single agents despite their availability.

Conclusions:

• Refractory PTCL patients face inferior outcomes compared to relapsed PTCL patients, even with modern therapies.
• Peripheral T-cell lymphoma remains a significant unmet medical need, highlighting the necessity for improved front-line treatment strategies.